A Novel Self-Expandable, Radioactive Airway Stent Loaded with 125I Seeds: A Feasibility and Safety Study in Healthy Beagle Dog

Wang, Yong; Guo, Jun; Zhu, Guangyu; Zhu, Hai-Dong; Chen, Li; Lü, Jian; Wang, Chao; Teng, Gao‐Jun

doi:10.1007/s00270-017-1639-8

Cited by 24 publications

(17 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the successful clinical application of a radioactive stent in patients with esophageal carcinoma or malignant biliary obstruction [ [12] , [13] , [14] ], the tracheal stent loaded with 125 I seeds was developed for preventing restenosis of the stent. The feasibility and safety of inserting such a radioactive stent into the airway have been demonstrated in the healthy beagle dog models [ 15 ]. In this prospective study, we aim to evaluate the safety and efficacy of this radioactive bare metal stent (RBMS) versus conventional bare metal stent (CBMS) in patients with inoperable MAO.…”

Section: Introductionmentioning

confidence: 99%

A Novel Tracheobronchial Stent Loaded with 125I Seeds in Patients with Malignant Airway Obstruction Compared to a Conventional Stent: A Prospective Randomized Controlled Study

Wang¹,

Lü²,

Guo³

et al. 2018

EBioMedicine

Self Cite

View full text Add to dashboard Cite

BackgroundTo evaluate the safety and efficacy of a novel radioactive bare metal stent (RBMS) compared with a conventional bare metal stent (CBMS) in patients with inoperable malignant airway obstruction.MethodsThis prospective study was approved by the Institutional Ethics Committee, and informed consent was obtained from each participant. Patients with malignant airway obstruction who had dyspnea were randomly assigned to receive RBMS or CBMS placement. The primary endpoint was stenosis grade, while the secondary endpoints were technical success, overall survival, and complications. A p value of <0·05 was considered statistically significant.ResultsBetween September 2013 and July 2015, 66 patients with inoperable malignant airway obstruction received stent placement fluoroscopically (33 in either group). The median follow-up time was 154 days (range, 15–335 days). The baseline stenosis was immediately relieved in both groups after stent placement, and the stenosis grades in the RBMS group were significantly lower than that in the CBMS group since the second month (p < 0·05). The technical success rates of stent placement were 100% in both groups. The median survival in the RBMS group was significantly longer than that in the CBMS group (170 days vs. 123 days, p < 0·05). There was no significant difference in the incidence of complications between the two groups (p < 0·05).ConclusionsThe placement of RBMS in patients with inoperable malignant airway obstruction is feasible and safe, and it significantly reduces restenosis and improves overall survival compared with the placement of CBMS.

show abstract

Section: Introductionmentioning

confidence: 99%

A Novel Tracheobronchial Stent Loaded with 125I Seeds in Patients with Malignant Airway Obstruction Compared to a Conventional Stent: A Prospective Randomized Controlled Study

Wang¹,

Lü²,

Guo³

et al. 2018

EBioMedicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…Interestingly, similar phenomena were observed in terms of DCR. 125 I brachytherapy is a type of low-dose-rate therapy because the dose delivered by RIS implanted permanently in place is <1 Gy per h. Meanwhile, 125 I brachytherapy can also be treated as high-dose-rate therapies, in which the radiation is delivered over several courses (36,37). The accumulated dose of tumor and efficacy increase as irradiation time moves along.…”

Section: Discussionmentioning

confidence: 99%

Oligorecurrence Non–small Cell Lung Cancer After Failure of First-Line Chemotherapy: Computed Tomography–Guided 125I Seed Implantation vs. Second-Line Chemotherapy

et al. 2020

Self Cite

View full text Add to dashboard Cite

Purpose: To compare the efficacy and safety of computed tomography (CT)-guided 125 I seed implantation with second-line chemotherapy in treatment of oligorecurrence non-small cell lung cancer after failure of first-line chemotherapy.Methods: Data of oligorecurrence non-small cell lung cancer patients after failure of first-line chemotherapy at two institutions were retrospectively reviewed from January 2013 to July 2018. A total of 53 patients who received the treatment of 125 I seed implantation or second-line chemotherapy were eligible for this study. In group A, 25 patients, 84 lesions, received CT-guided permanent 125 I seed implantation, whereas in group B, 28 patients, 96 lesions, received second-line chemotherapy. The outcomes were measured in terms of disease control rate, overall survival, quality of life, and complications.Results: The median follow-up period was 13 months (range, 5-42 months). Disease control rate in group A was higher than that in group B (70.8 vs. 42.3%, P = 0.042) at 6 months after treatment. The median overall survival was 12.8 months (95% confidence interval, 10.5-15.1 months) in group A and 15.2 months (95% confidence interval, 12.2-18.2 months) in group B, with no significant difference (P = 0.847). Since the fourth month, the number of patients in group A with a non-decreasing Karnofsky Performance Scale score was more than that in group B (P < 0.05). The incidence of grade 3 or higher complications especially hematologic toxicity in group A was significantly lower than that in group B (P < 0.05).Conclusion: Radioactive 125 I seed implantation is safe and feasible in selected non-small cell lung cancer patients with oligorecurrence after failure of first-line chemotherapy and seems to provide a better long-term quality of life in these patients compared with second-line chemotherapy.

show abstract

“…Recently, brachytherapy with interstitial RIS implantation has been used with promising results for the treatment of solid tumors, particularly in prostate tumors. 8 The insertion of self-expandable stents loaded with RIS has been established as a new treatment strategy, combining the advantages of rapid patency achievement and continuous brachytherapy administration to prevent obstruction. The modality was initially applied to treat unresectable esophageal cancer and was subsequently extended to biliary obstruction caused by various adenocarcinomas.…”

Section: Discussionmentioning

confidence: 99%

Intraluminal Brachytherapy Using a Self-Expandable Stent Loaded With Linear Iodine-125 Seeds in a Patient With Reiterative Recurrence of Cancer-Associated Vein Obstruction: A Case Report With 3 Months of Follow-Up

Gong

Song

et al. 2018

Vasc Endovascular Surg

View full text Add to dashboard Cite

Cancer-associated vein obstruction (CAVO) is a common complication in oncological patients, but the effective therapeutic options are scant. We report a patient with reiterative recurrent CAVO who was successfully treated with intraluminal brachytherapy using a self-expandable stent loaded with linear radioactive iodine-125 seeds (RIS) strand. During follow-up, her clinical symptoms were well improved. Three-month imaging follow-up revealed satisfactory patency of the iliofemoral vein, and the stents combined with RIS strands performed well. No serious complications associated with the implantation of stent and RIS strands were documented in any of the sessions. Intraluminal brachytherapy using a self-expandable stent loaded with linear RIS may be a safe and effective option for CAVO as long as it includes not only blood flow restoration but also brachytherapy administration for cancer.

show abstract

A Novel Self-Expandable, Radioactive Airway Stent Loaded with 125I Seeds: A Feasibility and Safety Study in Healthy Beagle Dog

Abstract: This study demonstrates that it is feasible and safe to insert this novel self-expandable airway stent loaded with I seeds in healthy beagle dog.

Cited by 24 publications

References 27 publications

A Novel Tracheobronchial Stent Loaded with 125I Seeds in Patients with Malignant Airway Obstruction Compared to a Conventional Stent: A Prospective Randomized Controlled Study

A Novel Tracheobronchial Stent Loaded with 125I Seeds in Patients with Malignant Airway Obstruction Compared to a Conventional Stent: A Prospective Randomized Controlled Study

Oligorecurrence Non–small Cell Lung Cancer After Failure of First-Line Chemotherapy: Computed Tomography–Guided 125I Seed Implantation vs. Second-Line Chemotherapy

Intraluminal Brachytherapy Using a Self-Expandable Stent Loaded With Linear Iodine-125 Seeds in a Patient With Reiterative Recurrence of Cancer-Associated Vein Obstruction: A Case Report With 3 Months of Follow-Up

Contact Info

Product

Resources

About